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Antoantibodies to GBM and neutrophil cytoplasm in rapidly progres-
sive glomerulonephritis. The incidence of autoantibodies to glomerular
basement membrane (AGBMA) and neutrophil cytoplasmic antigens
(ANCA) in the initial sera of 889 consecutive patients with a suspected
diagnosis of rapidly progressive glomerulonephritis, was determined by
prospective study. Forty-seven (5%) were positive for AGBMA alone,
246 (28%) were positive for ANCA alone, 576 (65%) had neither
autoantibodies while 20 (2%) had both. Clinical and pathological data
collected from patients with both autoantibodies suggested the coexis-
tence of anti-glomerular basement membrane disease and systemic
vasculitis. Together, assays for AGBMA and ANCA are important in
the diagnosis and management of rapidly progressive glomerulonephri-
tis and may help its further classification.
Rapidly progressive glomerulonephritis is a syndrome de-
fined by the clinical picture of renal failure developing over days
or weeks and the histological appearance of a severe crescentic
glomerulonephritis [1]. This finding is present in 8% of all renal
biopsies reported to the Medical Research Council glomerulo-
nephritis registry (A.M. Davison, personal communication). It
can occur in several clinical settings, such as anti-glomerular
basement membrane disease, systemic vasculitis and systemic
lupus erythematosus, suggesting it represents the result of a
variety of different pathogenetic processes [21.
Until recently the prognosis of rapidly progressive glomeru-
lonephritis has been poor and treatment empirical [3]. How-
ever, the discovery in anti-glomerular basement membrane
disease of circulating autoantibodies with specificity for the
glomerular basement membrane (AGBMA) and demonstration
of their pathogenicity by animal transfer experiments, has
allowed development of a rational form of treatment [41. Ther-
apy consists of plasma exchange to remove circulating auto-
antibodies, and immunosuppressive drugs to inhibit their further
synthesis [5]. Treatment is then monitored by immunoassay and
therapy tailored accordingly [6].
The same therapy is effective for rapidly progressive glomer-
ulonephritis associated with systemic vasculitis, such as We-
gener's granulomatosis and microscopic polyarteritis, and may
even be applied successfully when such patients are dialysis
dependent [7], whereas in anti-glomerular basement membrane
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disease recovery of renal function from dialysis dependence is
unusual [5]. In systemic vasculitis circulating anti-neutrophil
cytoplasm antibodies (ANCA) are a marker for diagnosis and
disease activity but their pathogenetic potential has not yet
been defined [8]. We have recently developed a similar radio-
immunoassay (RIA) for ANCA to that which we routinely use
to detect AGBMA [9].
By determining the incidence of AGBMA and ANCA in the
initial sera of patients with rapidly progressive glomerulone-
phritis, this study aimed to show the relevance of these assays
to its diagnosis and classification. During the course of the
study a number of patients were found to possess both auto-
antibodies. In view of the differences in response to treatment
and prognosis between anti-glomerular basement membrane
disease and systemic vasculitis the clinical and histological
features of these patients were collected and included in this
study.
Methods
Sera are routinely sent to this laboratory for estimation of
AGBMA and ANCA in patients with rapidly progressive gb-
merulonephritis. The initial samples received by this depart-
ment on 889 patients between November 1986 and July 1987
were studied. Samples were stored in aliquots at —20°C until
ready for testing.
AGBMA RIA
This assay has been available in our laboratory since 1980 [6].
In brief, polypropylene microtiter plates (Dynatech) were
coated with human GBM solubilized with collagenase at a
concentration of 15 sm/ml in phosphate buffered saline (PBS)
pH 7.2 by overnight incubation at 4°C. After washing with PBS
containing 0.1% Tween 20 (PBSTw), plates were incubated
with control (normal and reference positive) or test serum
samples (diluted 1/8 in PBSTw) for one hour at 37°C. After
further washing with PBSTw, bound AGBMA were detected by
incubation with anti-human IgG labelled with iodine 125 (4
sCi/g), in PBSTw at 37°C for one hour. All volumes were 100
pi. Plates were then washed in PBSTw and counted. Binding of
test serum samples was expressed as a percentage of the
reference positive serum sample. Binding of normal serum was
7.4 to 12.8% (mean 2 SD) binding of the reference positive
serum. Autoantibody specificity was checked by inhibition
assay, where test sera diluted 1/32 was pre-incubated in the fluid
phase with either GBM antigen (150 g/ml), a non-specific
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protein (hemoglobin), or PBS alone, and then entered into the
AGBMA assay. A reduction in binding of more than 15% with
GBM antigen compared to the controls was regarded as a
positive result.
ANCA RIA
An improved assay to that previously described was used [9].
Granulocytes were separated from fresh heparinized blood
from a normal donor, then layered onto a methyl-cellulose
hypaque gradient and washed in PBS. Contaminating red cells
were disrupted by a lysis buffer of 0.1 M ammonium chloride.
The cells were sonicated in 0.2 M sodium acetate pH 4.2 with
ice-cooling. The suspension was microfuged at 10,000 g for two
minutes and stored in glass at —70°C. The neutrophil extract (10
g/ml) was coated onto microtiter plates (Dynatech). Test or
control sera were added to the coated plates (1/8 dilution in
PBSTw containing 1% gelatin, PBSGe1Tw). Bound antibody
was detected by a triple layer technique of monoclonal mouse
anti-human IgG (Unipath) diluted 1/2000 in PBSGe1Tw, fol-
lowed by rabbit anti-mouse Ig (from D. Grennan) at 1/1000 in
PBSGe1Tw, and iodine-125-labelled goat anti-rabbit Ig (from
Professor J. Humphrey) specific activity 4 Ci/g. All volumes
were 100 .d and incubation times were one hour at 37°C. Plates
were washed three times between incubation steps with
PBSTw. After final washing the plates were counted in an LKB
1260 multichannel gammacounter. Results were expressed as a
percentage of a reference positive serum; binding of normal
serum was 8.4 to 15.4% (mean 2 SD), the binding of the
reference positive serum. An inhibition assay similar to that for
the AGBMA assay was performed on positive sera, using the
neutrophil extract at 50 Lg/m1 as specific inhibitor. Greater than
20% reduction in binding with the neutrophil extract in compar-
ison with the controls was a positive result.
Cross-inhibition RIA
To check for cross reactivity between the AGBMA and
ANCA RIAs, sera positive for both autoantibodies was re-
tested using the neutrophil extract (50 g/ml) as an inhibitor in
the AGBMA inhibition assay and GBM antigen (150 pg/ml) in
the ANCA inhibition assay. No significant reduction in binding
in either cross inhibition assay signified the presence of two
distinct autoantibody populations.
ANCA indirect immunofluorescence assay (hF)
This technique has been previously described [9]. In brief,
freshly isolated granulocytes were resuspended in RPMI 1640
containing 10% fetal calf serum at 2 x iO cells per ml.
Cytocentrifuge preparations of the cell suspension were made
up on glass slides, air dried, and fixed in pre-chilled alcohol (5
mm at 4°C). Test or control serum diluted 1/8 in PBS (20 .d) was
overlayed on the cytopreparations and incubated for one hour
at 4°C in a moist environment. Slides were then washed three
times in PBS for five minutes; bound antibody was detected by
a fluorescein-isothyocyanate conjugated rabbit antibody against
human immunoglobulin light chains (Dako) diluted 1/32 in PBS.
Finally the slides were washed and mounted in 90% glycerol in
PBS and examined under ultraviolet light. A sample was scored
as positive if the majority of neutrophils and monocytes showed
bright fluorescence in the cytoplasm. Two patterns of fluores-
cence have been described, cytoplasmic (CANCA) or pen-
nuclear (PANCA).
Immunoblotting of GBM antigens
This method has been previously described [10]. In brief,
collagenase solubilized human GBM was separated by discon-
tinuous sodium disuiphate polyacrylamide gel electrophoresis
(SDS-PAGE) on a 10% gradient. The upper stacking gel was 4%
and the acrylamide/bisacrylamide ratio was 30:1 throughout.
Antigen was diluted 1:1 with sample buffer (60 mM Tris-HCL
pH 6.8, containing 70 mM SDS, 20% glycerol and 5% B-
mercaptoethanol). Each gel was 25 ml volume and 1.5 mm
thick. Electrophoresis was completed overnight at 80 volts.
Transfer of separated antigen by electroblotting to nitrocellu-
lose filters took place overnight at 30 volts/0. 15 amps. The filter
was then incubated with AGBMA positive sera, sera positive
for both AGBMA and ANCA, and control sera. Antibody
binding was detected by an 1125 goat anti-human IgG (4 pCi/g,
as for the AGBMA assay).
Clinical and pathological data
Questionnaires were sent to the referring physicians of each
of the patients with both AGBMA and ANCA, requesting the
following information: presenting symptoms, age, sex, occupa-
tion, drug and smoking histories, family history, exposure to
hydrocarbons, renal manifestations including renal biopsy, in-
volvement of the respiratory tract or other systems, routine
hematology and biochemistry, auto-immune profile, treatment,
follow-up data and clinical diagnosis.
Results
Immunoassays
AGBMA RIA. Of 889 patients tested 67 (7.5%) were positive
(percentage binding 19 to 100%, mean 41%). Forty-seven (5%)
had AGBMA alone, while 20 (2%) were also ANCA positive.
Mean AGBMA binding tended to be higher for those with
AGBMA alone (45%) than for those with both AGBMA and
ANCA (33%) (Table 1, Fig. 1).
ANCA RIA. Two hundred and sixty-six (30%) were positive
for ANCA, 246 (28%) had ANCA alone and 20 (2%) were
double positive. Five hundred and seventy-six (65%) were
negative for both autoantibodies.
Cross inhibition RIA. All 20 patients with both AGBMA and
ANCA had less than 15% inhibition in the AGBMA RIA using
the neutrophil extract as inhibitor, and less than 20% inhibition
in the ANCA RIA using the GBM antigen as inhibitor.
ANCA hF. Eighteen of 20 (90%) of the patients with
AGBMA and ANCA were positive, 11 had the CANCA pattern
and seven had PANCA.
Immunoblotting of GBM antigens. Of the 20 double positive
sera, 18 (90%) produced bands consistent with those found in
sera positive for AGBMA alone at 54, 30 and 27 KD (Fig. 2, the
27 KD band has not reproduced). The two sera failing to
produce such bands had the lowest titers of AGBMA.
Clinical and pathological data
Clinical presentation. Twenty patients with both autoanti-
bodies (11 male, 9 female) were aged 13 to 73 years (mean 48
years). All had hematuria, 18 having an elevated serum creati-
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Table 1. Initial percent binding in AGBMA and ANCA RIAs, and
ANCA indirect immunofluorescence (IIF) of sera from patients with
AGBMA and ANCA (CANCA indicates cytoplasmic, PANCA pen-
nuclear neutrophil fluorescence)
Patient AGBMA RIA ANCA RIA
no. normal < 13% normal < 16% ANCA IIF
1 35 44 CANCA
2 28 61 CANCA
3 23 93 CANCA
4 20 77 CANCA
5 23 31 neg
6 79 19 CANCA
7 31 66 CANCA
8 27 29 PANCA
9 20 16 PANCA
10 20 44 PANCA
11 90 67 CANCA
12 30 22 neg
13 45 26 PANCA
14 32 100 CANCA
15 36 28 PANCA
16 40 62 CANCA
17 34 24 PANCA
18 20 71 CANCA
19 44 38 CANCA
20 42 63 PANCA
nine, eleven of whom required dialysis. There was evidence of
pulmonary hemorrhage in 13, two being regular smokers, none
had occupational exposure to hydrocarbons. Other extra-renal
involvement was present in 11, five having sinusitis, two
arthritis, two rash, and one each, temporal arteritis, cerebro-
vascular occlusion and corneal ulceration (Table 2). Initial
hemoglobin was 6.6 to 13.0 gIdl (mean 10.3), neutrophil count
4.0 to 16.6 x 109/liter (mean 9.0), platelets 94 to 593 X 109/Iiter
(mean 317), and ESR 15 to 75 mmlhr (mean 58). One patient had
a positive ANA at 1/80.
Renal histology. Biopsies were performed in 18 of 20 patients
and showed crescents in 17 with focal and segmental necrosis in
15; granulomata were seen in four and extra-glomerular vascu-
litis in one. On direct immunofluescence there was linear IgG in
capillary loops in 12 of 16, with additional granular deposits of
1gM or C3 in the glomeruli of eight (Table 3). A diagnosis based
on clinical and histological features of anti-glomerular basement
membrane disease was made in nine, Wegener's granulomato-
sis in two, microscopic polyarteritis in four and idiopathic
rapidly progressive glomerulonephritis in five.
Immunosuppressive treatment. Seventeen received pred-
nisolone and cyclophosphamide, ten also having plasma ex-
change; azathioprine was given in addition in two and cyclos-
porin A in one (Table 2).
Follow-up. By 6 to 15 months (mean 10) there had been five
deaths (mean 2 weeks alter presentation), which were charac-
terized by severe initial disease and an older average age (mean
66 yrs, mean 42 years for the survivors), Of the seven survivors
initially dialysis dependent, three had recovered satisfactory
renal function (serum creatinine 200 to 345 tmol/liter). Two
clinical disease relapses occurred, one at six months with
pulmonary hemorrhage (case 2), another at nine months with
both renal and pulmonary involvement (case 20). Both relapses
were associated with persistent ANCA positivity and negative
AGBMA.
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Fig. 1. Comparison of AGBMA percent at presentation between those
with AGBMA alone and those positive for both AGBMA + ANCA
(dotted line indicates upper limit of the normal range, horizontal bars
indicate means).
Discussion
Rapid serum assays for AGBMA and ANCA speed the
diagnosis and thereby may improve the prognosis of rapidly
progressive glomerulonephritis. Treatment must be started
early for optimal recovery of renal function and in the past
diagnosis has depended on renal biopsy. In anti-glomerular
basement membrane disease, recovery of renal function once
the patient is dialysis dependent is unusual and in systemic
vasculitis, clinical outcome correlates with the severity of renal
injury [5, 12]. We have previously shown ANCA positivity to
be specific for SV, while AGBMA are considered to be specific
for anti-glomerular basement membrane disease [9, 6]. This
study has assessed the incidence of these two autoantibodies,
and therefore the incidence of the underlying diseases, in
patients with rapidly progressive glomerulonephritis. Interest-
ingly, the ratio of AGBMA to ANCA positivity in all sera
studied was one to four; the same ratio is seen when relating the
incidence of linear to non-linear glomerular immunoglobulin
deposits in renal biopsies of rapidly progressive glomerulone-
phritis sent to the Medical Research Council Glomerulonephri-
tis Registry (A.M. Davison, personal communication).
A subgroup of patients with both AGBMA and ANCA has
been identified. Retrospectively this may have been predicted
by case reports of the co-existence of anti-glomeriilar basement
membrane disease and Wegener's granulomatosis, and by the
presence of vasculitis in the renal biopsies of patients with
anti-glomerular basement membrane disease [11, 13]. Prodro-
mal symptoms, such as malaise, weight loss and rashes, and
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Fig. 2. Immunoblot of GBM antigen overlayed with sera positive for AGBMA alone [1, 2], AGBMA and ANCA [3, 4], ANCA alone [5, 6] and
normal controls [7, 8] (The 27 kd band has not reproduced.).
Table 2. Clinical presentation, treatment, diagnosis and outcome of patients positive for AGBMA and ANCA
No. Age Sex Hematuria
Lung
hematuria
Other system
involvement
Creatinine pinol/liter
Treatment
.Clinical
diagnosisOnset Follow-up
1 47 F + + rash D 315 P Cy PE anti-GBM
2 13 M + + rash, sinusitis D D P Cy PE anti-GBM
3 20 M + +* sinusitis
arthritis
N N P Cy WG
4 59 M + — temporal
arteritis
196 230 P Cy PE RPGN
5 47 M + — sinusitis, corneal
melting syndrome
N N MP Cy CsA MPA
6 59 F + + — D D P Cy PE anti-GBM
7 69 F + — — 395 400 P Cy RPGN
8 36 M + — — D D P Cy anti-GBM
9 17 F + — — D D PCyAzPE RPGN
10 63 M + + pharyngitis D 345 P Cy PE MPA
11 35 F + — — D 200 P Cy PE anti-GBM
12 35 M + — deafness 210 D PCy RPGN
13 60 F + + cerebro-vascular
accident
D died none MPA
14 64 F 1- + — D died P Cy PE anti-GBM
15 24 F + + — N N P Cy PE anti-GBM
16 56 M + + — 132 365 PCyPE MPA
17 70 M + +* arthritis 395 died none RPGN
18 73 M + + sinusitis D died P Cy WG
19 65 F + + — D died P Cy PE anti-GBM
20 57 M + + sinusitis 600 600 P Cy AZ anti-GBM
Abbreviations are: D, dialysis; N, normal; *, smokers; P, prednisolone; Cy, cyclophosphamide; Az, azathioprine; CsA, cyclosporin A; MP,
methyl prednisolone; PE, plasma exchange; anti-GBM, anti-glomerutar basement membrane disease; WG, Wegener's granulomatosis; MPA,
microscopic polyarteritis; RPGN, idiopathic rapidly progressive glomerulonephntis.
organ involvement outside the lungs and kidneys, are more
frequent in systemic vasculitis than in anti-glomerular basement
membrane disease [14]. This subgroup had disease outside the
renal and pulmonary systems in 12 of 20 patients (60%). Renal
disease was severe, with 11 of 20 (55%) being dialysis depen-
dent at presentation, slightly less than the 73% reported in a
recent study of anti-glomerular basement membrane disease
[5]. The incidence of pulmonary hemorrhage (45%) lies between
that reported for systemic vasculitis (29 to 42%) and that for
anti-glomerular basement membrane disease (60 to 90%) [14—
16].
Two features of clinical importance were seen in the follow-
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Table 3. Renal immunohistology of patients positive with AGBMA and ANCA
No. Crescents
Focal and
segmental
necrosis
Other features
on LM Linear IF Granular IF
Extra-
glomerular
vascular IF
1 + 70% + granulomata C3 — —
2 + + — IgG C3 —
3 + 10% + Interstitial
nephritis
— 1gM C3 —
4 +80% + — IgG 1gM —
5 no biopsy
6 + 100% + granulomata
vasculitis
IgG 1gM
IgA C3
1gM C3 1gM IgA
C3
7 +50% — — noIF
8 + — IgG —
9 + 20% + glomeruler
sclerosis
IgG 1gM C3 —
10 + 95% + glomeruler
sclerosis
IgG — C3
11 + 50% + granulomata IgG C3 C3
12 + 70% + transplant
rejection
IgO 1gM 1gM ClO —
13 + 100% + glomerular
sclerosis
IgG C3
14 +95% + — noIF —
15 none — minor abn. IgG — —
16 +90% + — — — —
17 no biopsy
18 + 100% + — — lgG 1gM C3 1gM C3
19 + 100% + granulomata IgG C3 — —
20 +75% + — IgG — —
up of the patients with ANCA and AGBMA: the recovery of onset relapse
renal function in 3 of 7 survivors initially dialysis dependent and
the recurrence of disease activity many months after clinical
remission in two. Both are rare in anti-glomerular basement
membrane disease but common in systemic vasculitis, and a
vasculitic etiology for the recurrences is supported by the
persistance of ANCA [5, 7, 17].
Surprisingly, ANCA positivity was found in as many as 20 of
67 (30%) cases with AGBMA. Analysis of the renal histology of
this subgroup supported the serological evidence of two dis-
eases; the presence of linear IgG confirming anti-glomerular 50
basement membrane disease, but additional granular glomeru- I
lar deposits coupled with granulomata and extra-glomerular A..
vasculitis point to a second simultaneous pathogenic process. A N. A
The possible contribution of an ANCA associated injury in I I
anti-glomerular basement membrane disease may help explain -s
the poor correlation previously observed between circulating k
AGBMA binding and disease severity, the subgroup with both 25 -
AGBMA and ANCA tending to have a lower AGBMA than the t
group with AGBMA along (Fig. 1). Although in the patients $
with AGBMA and ANCA both autoantibodies were present .
. . \j.. . . . .
initially, sequential studies of autoantibody titer suggest differ- \
ences in their immunoregulation (Fig. 3). N
In conclusion, the ANCA assay has contributed to a serolog- 4...- •
ical classification of rapidly progressive glomerulonephritis by
______________________________________________identifying two new categories, one with ANCA alone and one 1)0 100 200 300 400
with both AGBMA and ANCA. This second subgroup has Time, days
clinical and histological features of both anti-glomerular base- Fig. 3. Sequent iaIAGBMA andANCA from patient No. 20. Onset and
ment membrane disease and systemic vasculitis, and accounts relapse of clinical disease is indicated by arrows. Symbols are: (—)
for a significant proportion of all cases with AGBMA. In view of AGMA; (....)ANCA.
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the differences in prognosis between anti-glomerular basement
membrane disease and systemic vasculitis, it is important to
characterize the clinical implications of dual positivity for
ANCA and AGBMA by further comparative study.
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